Cutanos GmbH is a viennese biotech company founded in early 2021 focussing on preclinal development of antigen-specific vaccines and new treatments for autoimmune disorders. Cutanos uses a modular and highly flexible drug delivery system called the Langerhans Cell Targeted Delivery System (LC-TDS). With this technology, the company aims to realize innovative immunotherapies in conjunction with minimally invasive administration.
Althanstraße 14 (UZA II)
1090 Wien
Vienna
Contact: Robert Wawrzinek (Managing Director)
Email: info@cutanos.com
Website